• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Controversies in Modern Eye Care 2023: Evolving therapeutics for nAMD and DME


David Liao, MD, shares highlights from his discussion on evolving treatment strategies for neovascular AMD and DME, during the 17th annual Controversies in Modern Eye Care meeting.

David Liao, MD, of Retina Vitreous Associates Medical Group, shares highlights from his breakfast symposium, "Keeping an eye on evolving management strategies for nAMD and DME," which he co-presented during the 17th annual Controversies in Modern Eye Care symposium at the Skirball Cultural Center in Los Angeles, California.

This transcript has been edited for clarity.

David Liao, MD:

My name is David Liao, I'm with Retina Vitreous Associates here in Los Angeles. Today I'm gonna be speaking about evolving treatment strategies for neovascular AMD and DME. We're going to be going through a little bit of the history of how we got to where we are today, starting with the initial pivotal trials and fixed dosing regimens, and then we'll move on to the evolution of PRN treatment, and where we are today with some new medications, as well as the treatment extend protocol. And I think we'll see how the treatment has evolved over the years to minimize treatment burden and continue with good efficacy, as well.

You know, with all of these years of evolving treatments, we've kind of focused now on a more patient-centered approach. So it's individualize not only for the patient, but for their specific disease. And I think that really—the patients like it more, there's less risk for them, there's less burden of coming in, and it really keeps their disease really in control. So it's not too much treatment, but not too little either.

Related Videos
Megan Cavet, PhD
© 2024 MJH Life Sciences

All rights reserved.